M-A: GLP-1 receptor agonists reduce major adverse cardiovascular events, all-cause mortality, hospital admission for heart failure, and worsening kidney function in patients with type 2 diabetes.

Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials – The Lancet Diabetes & Endocrinology (link to abstract – $ for full-text)

Related: Guideline: SGLT-2 inhibitors or GLP-1 receptor agonists for adults with type 2 diabetes – This guidance recommends a risk-based approach, advising against starting SGLT-2 inhibitors or GLP-1 receptor agonists in patients with three or fewer cardiovascular risk factors and without established CVD or CKD.